Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 30, 2025 16:05 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
January 28, 2025 21:30 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Announces Proposed Public Offering of Common Stock
January 27, 2025 16:01 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
January 27, 2025 06:30 ET
|
Akero Therapeutics Inc.
Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over...
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET
|
Akero Therapeutics Inc.
Investor webcast on Monday, January 27, 2025, at 8:00 a.m. ET to present clinical data SOUTH SAN FRANCISCO, Calif., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a...
Akero Therapeutics Completes Enrollment of the Double-Blind Portion of the Phase 3 SYNCHRONY Real-World Study Evaluating Efruxifermin (EFX) in Patients with Non-Invasively Diagnosed MASH or MASLD
January 13, 2025 07:00 ET
|
Akero Therapeutics Inc.
-- 601 patients have been enrolled in the double-blind portion of the SYNCHRONY Real-World study since initiation in November 2023 -- -- Data from SYNCHRONY Real-World study anticipated in the first...
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
January 07, 2025 07:00 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present at the 7th Annual Evercore ISI HealthCONx Conference
November 26, 2024 07:00 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
November 15, 2024 11:00 ET
|
Akero Therapeutics Inc.
-- Over 40% of participants treated with EFX 50mg for 96 weeks, compared with 0% for placebo, showed regression of liver fibrosis by all of three orthogonal measures: (1) ≥1-stage fibrosis improvement...
Akero Therapeutics to Present at the Jefferies London Healthcare Conference
November 13, 2024 16:05 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...